Norway, Oct. 8 -- Circio Holding ASA, a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, today announces the publication of a comprehensive data package demonstrating AAV-circVec in vivo tissue-specific proof-of-concept. The results are being delivered in a poster presentation at the European Society of Cell and Gene Therapy (ESGCT) annual meeting 2025 in Seville, Spain. In the ESGCT poster presentation, Circio is presenting new and expanded in vivo results demonstrating the advantage of circVec as a novel expression system to transform AAV gene therapy. In heart tissue, circVec 3.2 shows highly localized activity that outperforms conventional mRNA-based AAV expression by up to 40-...